Chase Therapeutics
AcquiredMountain View, United States · $20.0M raised
- Headquarters
- Mountain View, California
- Employees
- 1–10
- Business Model
- B2B
- Total Funding
- $20.0M
- Last Round
- $20.0M Series BDec 2021
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round for this company. The full record is or through the API.
About
Chase Therapeutics Corporation was an early-stage specialty pharmaceutical company focused on developing novel dopamine agonist combination therapies for brain diseases, with lead programs targeting treatment-resistant depression (CTC-501/ALTO-207) and Parkinson's disease (CTC-413/ALTO-208). The company completed Phase 2a clinical trials for both candidates, demonstrating statistically significant clinical effects. In June 2025, Alto Neuroscience acquired Chase Therapeutics' full pipeline via an asset purchase agreement for $1.75 million upfront plus up to $71.5 million in future milestone payments.
Summary
Chase Therapeutics is a Biotech company based in Mountain View, United States. It has raised $20.0M in total across 1 round, most recently a $20.0M Series B round in Dec 2021.
Funding History
Dec 2021
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/chase-therapeutics"><img src="https://indexed.vc/api/badge/company/chase-therapeutics" alt="Chase Therapeutics on Indexed.vc" width="260" height="76" /></a>